Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Past Earnings Performance
Past criteria checks 5/6
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt has been growing earnings at an average annual rate of 23.5%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 11.8% per year. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's return on equity is 17.3%, and it has net margins of 25.2%.
Key information
23.5%
Earnings growth rate
23.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 11.8% |
| Return on equity | 17.3% |
| Net Margin | 25.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 839,601 | 211,635 | 207,702 | 89,283 |
| 30 Jun 24 | 811,415 | 229,129 | 203,363 | 84,358 |
| 31 Mar 24 | 798,937 | 187,874 | 199,584 | 83,924 |
| 31 Dec 23 | 805,158 | 158,850 | 196,619 | 78,344 |
| 30 Sep 23 | 825,948 | 95,563 | 201,667 | 78,574 |
| 30 Jun 23 | 855,211 | 123,426 | 199,704 | 77,387 |
| 31 Mar 23 | 844,351 | 157,720 | 191,469 | 75,290 |
| 31 Dec 22 | 802,755 | 169,076 | 182,350 | 75,109 |
| 30 Sep 22 | 755,061 | 242,521 | 165,816 | 68,730 |
| 30 Jun 22 | 694,772 | 198,297 | 155,135 | 66,489 |
| 31 Mar 22 | 657,758 | 149,792 | 146,773 | 62,419 |
| 31 Dec 21 | 630,595 | 139,626 | 143,261 | 61,005 |
| 30 Sep 21 | 604,708 | 114,689 | 139,575 | 59,304 |
| 30 Jun 21 | 584,887 | 99,067 | 136,059 | 56,079 |
| 31 Mar 21 | 566,244 | 102,570 | 132,525 | 54,418 |
| 31 Dec 20 | 566,776 | 104,683 | 133,766 | 53,977 |
| 30 Sep 20 | 555,124 | 68,482 | 134,358 | 55,110 |
| 30 Jun 20 | 544,964 | 68,130 | 137,596 | 53,745 |
| 31 Mar 20 | 527,608 | 54,123 | 144,866 | 52,273 |
| 31 Dec 19 | 507,794 | 47,135 | 145,281 | 48,860 |
| 30 Sep 19 | 490,668 | 49,451 | 144,043 | 46,258 |
| 30 Jun 19 | 462,576 | 36,071 | 143,720 | 43,363 |
| 31 Mar 19 | 453,151 | 42,857 | 141,650 | 40,903 |
| 31 Dec 18 | 445,484 | 35,348 | 139,654 | 40,545 |
| 30 Sep 18 | 434,078 | 11,939 | 140,523 | 41,576 |
| 30 Jun 18 | 441,997 | 18,899 | 139,253 | 40,768 |
| 31 Mar 18 | 445,626 | 2,997 | 139,412 | 41,027 |
| 31 Dec 17 | 444,356 | 8,885 | 138,256 | 39,903 |
| 30 Sep 17 | 439,822 | 68,291 | 137,882 | 37,763 |
| 30 Jun 17 | 429,207 | 66,829 | 136,121 | 36,317 |
| 31 Mar 17 | 413,021 | 74,992 | 131,932 | 35,489 |
| 31 Dec 16 | 389,690 | 66,200 | 127,903 | 35,153 |
| 30 Sep 16 | 372,689 | 52,016 | 122,486 | 32,401 |
| 30 Jun 16 | 368,539 | 44,525 | 120,792 | 33,588 |
| 31 Mar 16 | 366,889 | 50,419 | 118,318 | 33,813 |
| 31 Dec 15 | 365,220 | 53,863 | 117,707 | 34,822 |
| 30 Sep 15 | 366,631 | 40,482 | 117,110 | 40,072 |
| 30 Jun 15 | 362,903 | 39,300 | 119,714 | 42,380 |
| 31 Mar 15 | 353,080 | 30,652 | 119,713 | 42,996 |
| 31 Dec 14 | 353,709 | 24,950 | 121,315 | 43,666 |
| 30 Sep 14 | 355,043 | 31,723 | 126,411 | 43,069 |
| 30 Jun 14 | 348,768 | 37,367 | 123,446 | 42,308 |
| 31 Mar 14 | 354,346 | 33,058 | 126,467 | 41,371 |
| 31 Dec 13 | 351,886 | 42,766 | 126,317 | 40,800 |
Quality Earnings: RIG2 has high quality earnings.
Growing Profit Margin: RIG2's current net profit margins (25.2%) are higher than last year (11.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RIG2's earnings have grown significantly by 23.5% per year over the past 5 years.
Accelerating Growth: RIG2's earnings growth over the past year (121.5%) exceeds its 5-year average (23.5% per year).
Earnings vs Industry: RIG2 earnings growth over the past year (121.5%) exceeded the Pharmaceuticals industry 28.7%.
Return on Equity
High ROE: RIG2's Return on Equity (17.3%) is considered low.